Edwards Lifesciences opened higher at $94.55, compared with its previous close of $94.44. In the last trading session, the stock traded between $93.08 and $95.34. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Edwards Lifesciences is now worth
$ 77.71
resulting in a loss of
$ 22.29 (22.29%)
Note: Past profits do not guarantee future returns.
Rating from 11 Analysts
Today's Change
$-1.33 (-1.40%)
Day High
$95.34
Day Low
$93.08
Day Open
$94.55
Prev Close
$94.44
Volume
17,60,958
1W Return
3.36%
1M Return
5.72%
3M Return
8.55%
6M Return
14.65%
1Y Return
12.61%
Market Cap ($ Mn)
53,671
PE Ratio
53.70
PB Ratio
4.90
PEG Ratio
8.06
ROE
10.31%
ROCE
9.56%
EPS (TTM)
$0.42
1 Week
3.36%
1 Month
5.72%
3 Months
8.55%
6 Months
14.65%
9 Months
14.27%
Edwards Lifesciences faces high-risk FDA alert after device failure causes death
FDA issued a high-risk early alert for Edwards Lifesciences' Commander M delivery system on October 5. Three reports of balloon bursts resulted in one patient death and one serious injury. Four specific lots of the SAPIEN M3 delivery system are subject to immediate recall. Affected devices are used for transcatheter mitral valve replacements in non-surgical candidates.
14 days agoEdwards Lifesciences gets FDA approval for expandable pediatric heart valve
Edwards Lifesciences received FDA approval for the AUTUS Size-Adjustable Valve. First surgical pulmonary valve with synthetic polymeric leaflets approved for any use. Valve expands from 13 mm to 22 mm via transcatheter procedure to accommodate growth. Clinical trial showed 100% success rate with no deaths or strokes in 62 patients. Approval aims to reduce need for repeat open-heart surgeries in pediatric patients.
28 days agoEdwards Lifesciences delivers 16.73% average annual return over 20 years
A $100 investment in Edwards Lifesciences 20 years ago is worth $2,197.52 today at a share price of $85.52. The company delivered an average annual return of 16.73% over the 20-year period. Edwards Lifesciences outperformed the market by 7.57% on an annualised basis. The company's current market capitalisation stands at $49.29 billion.
1mo agoEdwards Lifesciences maintains 2026 guidance after CMS TAVR NCD
Edwards Lifesciences maintains its 2026 financial guidance following the CMS NCD for TAVR. The updated policy expands patient access and reinforces the multidisciplinary Heart Team approach. Implementation of the NCD is expected to take time, with longer-term guidance due in December. The company cites streamlined care pathways as key to reducing delays in aortic stenosis treatment.
1mo agoEdwards Lifesciences to present at Deutsche Bank Healthcare Summit
Edwards Lifesciences (NYSE: EW) to present at Deutsche Bank Healthcare Summit on Sept. 16, 2026. CEO Bernard Zovighian scheduled to speak at 10:00 a.m. ET. CFO Doretta Mistras will also participate in the conference. Live webcast available on company investor relations site.
1mo agoEdwards Lifesciences stock up 726% in 15 years, beating market
Edwards Lifesciences shares have risen significantly over the last 15 years, turning a $100 investment into $826.43. The stock achieved a 15.06% annualized return, exceeding market performance by 1.31%, with the company now valued at $53.35 billion.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 | |
| $32.00 | -1.14% | $28,075.23M | 89.05 |
An investment of $100 made 5 years ago in Edwards Lifesciences is now worth
$ 77.71
resulting in a loss of
$ 22.29 (22.29%)
Note: Past profits do not guarantee future returns.
